Skip to main content

Table 4 Treatment-related adverse events

From: A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

Frequency n (%)

Alectinib

(n = 43)

Ceritinib

(n = 22)

Any Grade

Grade 3–5

Any Grade

Grade 3–5

 Nausea

4 (9.3)

1 (2.3)

6 (27.3)

2 (9.1)

 Diarrhea

2 (4.7)

0

8 (36.4)

3 (13.6)

 Vomiting

3 (6.9)

0

4 (18.2)

1 (4.5)

 Elevation of AST/ALT

10 (23.3)

3 (6.9)

3 (13.6)

1 (4.5)

 Peripheral edema

2 (4.7)

0

2 (9.1)

0

 Blurred vision

1 (2.3)

0

0

0

 Myalgia

5 (11.6)

1 (2.3)

0

0

 Dose reduction

3 (6.9)

5 (22.7)

 Treatment discontinuation

1 (2.3)

0

  1. AST aspartate transaminase; ALT alanine transaminase